BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 223 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,965,832 | -79.2% | 353,961 | -74.7% | 0.03% | -79.1% |
Q1 2024 | $43,177,275 | -3.3% | 1,396,419 | +26.3% | 0.16% | -10.2% |
Q4 2023 | $44,648,776 | +35.5% | 1,105,989 | -11.5% | 0.18% | +8.0% |
Q3 2023 | $32,953,481 | +299.6% | 1,249,658 | +160.6% | 0.16% | +317.9% |
Q2 2023 | $8,246,557 | -52.3% | 479,451 | -54.0% | 0.04% | -54.7% |
Q1 2023 | $17,284,418 | +259.6% | 1,042,486 | +65.3% | 0.09% | +218.5% |
Q4 2022 | $4,806,018 | -41.1% | 630,711 | -23.2% | 0.03% | -38.6% |
Q3 2022 | $8,161,000 | +892.8% | 821,061 | +806.7% | 0.04% | +1000.0% |
Q2 2022 | $822,000 | -81.7% | 90,551 | -79.5% | 0.00% | -84.0% |
Q1 2022 | $4,486,000 | +14.2% | 441,963 | +87.7% | 0.02% | +19.0% |
Q4 2021 | $3,927,000 | -53.6% | 235,418 | +97.8% | 0.02% | -70.4% |
Q4 2020 | $8,464,000 | +46.6% | 119,021 | -22.7% | 0.07% | +47.9% |
Q3 2020 | $5,773,000 | +205.6% | 153,875 | +165.6% | 0.05% | +118.2% |
Q2 2020 | $1,889,000 | – | 57,941 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |